Why Icosavax Stock Is Skyrocketing Today


Icosavax Inc ICVX shares are trading higher by 45.63% to $12.99 Thursday morning on continued strength after the company provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against respiratory syncytial virus.

The six-month immunogenicity update from the company's Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV) demonstrated a sustained neutralizing antibody (nAb) response against RSV, lasting at least six months after a single administration of IVX-121.

IVX-121 continued to be generally well-tolerated, with no safety concerns observed in this six-month follow-up and no vaccine-related serious adverse events (SAEs)...Read More

According to data from Benzinga Pro, Icosavax has a 52-week high of $25.63 and a 52-week low of $2.28.

Market News and Data brought to you by Benzinga APIs
Posted In: Small CapMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!